Anthony B. Rodriguez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Anthony B. Rodriguez has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Mark R. Conaway
Division of Translational Research and Applied Statistics, Department of Public Health Sciences, University of Virginia
9 shared publications - Victor H. Engelhard
Microbiology, Immunology and Cancer Biology, University of Virginia
9 shared publications - Amanda M. Briegel
Carter Immunology Center, University of Virginia, Charlottesville, Virginia
8 shared publications - Craig L. Slingluff
Department of Surgery/Division of Surgical Oncology and the Human Immune Therapy Center, Cancer Center, University of Virginia, Charlottesville, USA
8 shared publications Katarzyna Stasiak
8 shared publications- Marit Melssen
Immunology, Genetics & Pathology, Uppsala University, Uppsala, Sweden
8 shared publications
Latest Publications
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Movie S3 from Differential Expression of CD49a and CD49b Determines Localization and Function of Tumor-Infiltrating CD8+ T Cells
Movement of cells in anti-CD49a treated tumor slices
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Movie S3 from Differential Expression of CD49a and CD49b Determines Localization and Function of Tumor-Infiltrating CD8+ T Cells
Movement of cells in anti-CD49a treated tumor slices
- Open Access
- 1 July 2021
- Published by Elsevier in Cell Reports
- Vol. 36 (3) , 109422
Immune mechanisms orchestrate tertiary lymphoid structures in tumors via cancer-associated fibroblasts
- 1 July 2021
- Published by Elsevier in Cell Reports
- Vol. 36 (3) , 109422
Open AccessImmune mechanisms orchestrate tertiary lymphoid structures in tumors via cancer-associated fibroblasts
- Open Access
- 25 September 2017
- Published by Public Library of Science (PLoS) in PLOS Pathogens
- Vol. 13 (9) , e1006572
A single gp120 residue can affect HIV-1 tropism in macaques
Species-dependent variation in proteins that aid or limit virus replication determines the ability of lentiviruses to jump between host species. Identifying and overcoming these differences facilitates the development of animal models for HIV-1, including models based on chimeric SIVs that express HIV-1 envelope (Env) glycoproteins, (SHIVs) and simian-tropic HIV-1 (stHIV) strains. Here, we demonstrate that the inherently poor ability of most HIV-1 Env proteins to use macaque CD4 as a receptor is improved during adaptation by virus passage in macaques. We identify a single amino acid, A281, in HIV-1 Env that consistently changes during adaptation in macaques and affects the ability of HIV-1 Env to use macaque CD4. Importantly, mutations at A281 do not markedly affect HIV-1 Env neutralization properties. Our findings should facilitate the design of HIV-1 Env proteins for use in non-human primate models and thus expedite the development of clinically relevant reagents for testing interventions against HIV-1. Understanding the interactions between viruses and their hosts allows manipulation of primate lentiviruses and the generation of better animal models for HIV/AIDS. Species-dependent differences in cellular proteins that play key roles in virus replication, such as the primary HIV-1 receptor CD4, can limit virus tropism. Our data reveal how adaptation in macaques improves the ability of HIV-1 envelope glycoproteins to use macaque CD4. Moreover, we identify a single amino acid in the HIV-1 envelope glycoprotein CD4 binding site that improves macaque CD4 use by most HIV-1 envelope proteins tested and allows viruses expressing these proteins to replicate efficiently in macaque cells without compromising their sensitivity to various antibodies. These findings should facilitate the development and preclinical evaluation of HIV-1 Env directed prophylactic and therapeutic interventions.
- 25 September 2017
- Published by Public Library of Science (PLoS) in PLOS Pathogens
- Vol. 13 (9) , e1006572
Open AccessA single gp120 residue can affect HIV-1 tropism in macaques
Species-dependent variation in proteins that aid or limit virus replication determines the ability of lentiviruses to jump between host species. Identifying and overcoming these differences facilitates the development of animal models for HIV-1, including models based on chimeric SIVs that express HIV-1 envelope (Env) glycoproteins, (SHIVs) and simian-tropic HIV-1 (stHIV) strains. Here, we demonstrate that the inherently poor ability of most HIV-1 Env proteins to use macaque CD4 as a receptor is improved during adaptation by virus passage in macaques. We identify a single amino acid, A281, in HIV-1 Env that consistently changes during adaptation in macaques and affects the ability of HIV-1 Env to use macaque CD4. Importantly, mutations at A281 do not markedly affect HIV-1 Env neutralization properties. Our findings should facilitate the design of HIV-1 Env proteins for use in non-human primate models and thus expedite the development of clinically relevant reagents for testing interventions against HIV-1. Understanding the interactions between viruses and their hosts allows manipulation of primate lentiviruses and the generation of better animal models for HIV/AIDS. Species-dependent differences in cellular proteins that play key roles in virus replication, such as the primary HIV-1 receptor CD4, can limit virus tropism. Our data reveal how adaptation in macaques improves the ability of HIV-1 envelope glycoproteins to use macaque CD4. Moreover, we identify a single amino acid in the HIV-1 envelope glycoprotein CD4 binding site that improves macaque CD4 use by most HIV-1 envelope proteins tested and allows viruses expressing these proteins to replicate efficiently in macaque cells without compromising their sensitivity to various antibodies. These findings should facilitate the development and preclinical evaluation of HIV-1 Env directed prophylactic and therapeutic interventions.